

VR22 Antibody (Center) Blocking Peptide

Synthetic peptide Catalog # BP8936c

Specification

VR22 Antibody (Center) Blocking Peptide - Product Information

Primary Accession <u>Q9UI47</u>

VR22 Antibody (Center) Blocking Peptide - Additional Information

Gene ID 29119

Other Names

Catenin alpha-3, Alpha T-catenin, Cadherin-associated protein, CTNNA3 {ECO:0000312|EMBL:AAF218011, ECO:0000312|HGNC:HGNC:2511}

Target/Specificity

The synthetic peptide sequence used to generate the antibody AP8936c was selected from the Center region of human VR22. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.

Format

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

Storage

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

Precautions


This product is for research use only. Not for use in diagnostic or therapeutic procedures.

VR22 Antibody (Center) Blocking Peptide - Protein Information

Name CTNNA3

VR22 Antibody (Center) Blocking Peptide - References

Kim,S.H., et.al., Clin. Exp. Allergy 39 (2), 203-212 (2009)Morgan,A.R., et.al., Am. J. Med. Genet. B Neuropsychiatr. Genet. 147B (6), 727-731 (2008)





{ECO:0000312|EMBL:AAF21801.1, ECO:0000312|HGNC:HGNC:2511}

Function

May be involved in formation of stretch-resistant cell-cell adhesion complexes.

Cellular Location

Cytoplasm, cytoskeleton. Note=Localizes to intercalated disks of cardiomyocytes and in peritubular myoid cells of testis, and colocalizes with CTNNA1 and CTNNA2.

Tissue Location

Predominantly expressed in heart and testis. Expressed at lower levels in brain, kidney, liver and skeletal muscle

VR22 Antibody (Center) Blocking Peptide - Protocols

Provided below are standard protocols that you may find useful for product applications.

• Blocking Peptides